drugset / Trial / NCT02320149

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

NCT02320149

Phase 3 Completed 968 enrolled Almirall, S.A. Allergan · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

Timeline

Start
2014-12-18
Primary completion
2017-02-01
Completion
2017-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarecycline Small molecule 1.5 mg/kg Oral

Indications